The Antibody Discovery and Development Seminar, hosted by Johns Hopkins Technology Ventures and Bluefield Innovations, will review Bluefield Innovation’s Fall 2019 funding cycle, through which investigators can secure multi-million dollar project funding, which to-date have provided JHU faculty with more than $30M in funding commitments so far.
The event on September 24 will consist of an expert-led seminar that explores state-of-the-art antibody therapeutic discovery. There will be presentations by John Toscano, vice dean of natural sciences in the Department of Chemistry; Joe Pearlberg, vice president of scientific affairs for Deerfield; and Larry Green, founder and CEO of Ablexis and CEO, AlivaMab Discovery Service.
Ablexis created and commercializes the AlivaMab Mouse technology, a unique, patented next-generation transgenic mouse platform for human therapeutic antibody discovery and antibody drug development. From university labs to large biopharma companies, Ablexis and Deerfield Management have created a widely utilized antibody drug discovery platform. Johnson & Johnson is one of the latest companies to use the AlivaMab mouse to find antibody-drug candidates for choice targets.
For questions, contact Nicole Snell at [email protected].
